Shares of Hims & Hers Health jumped after the company added former Food and Drug Administration official Deb Autor to its board. The stock was up 8.8% at $21.02 in Monday trading. Shares have doubled ...

Those ever-present TV drug ads showing patients hiking, biking or enjoying a day at the beach could soon have a different ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Amazon acquired primary care provider One Medical for $3.9 billion in 2022, and fills prescriptions through Amazon One ...

Waystar upped its 2024 outlook and now expects total revenue to range between $926 million and $934 million, compared to ...

The expanded services help customers receive consultations and medications for erectile dysfunction, men’s hair loss, eyelash growth, motion sickness, and anti-aging skin care.

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

Shares of Hims & Hers (HIMS) are sliding on Thursday after Amazon (AMZN) announced the launch of its Amazon One Medical Pay-per-visit ...

Hims & Hers (HIMS) fell 22% after Amazon (AMZN) announced it was entering the hair loss and erectile dysfunction treatment ...